<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129543</url>
  </required_header>
  <id_info>
    <org_study_id>20080899</org_study_id>
    <nct_id>NCT02129543</nct_id>
  </id_info>
  <brief_title>Immune Reconstitution in Stem Cell Transplant Recipients</brief_title>
  <official_title>Collection of Peripheral Blood Samples From Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This specimen collection lab protocol will allow the investigators to prospectively study
      immune reconstitution in patients being treated for hematologic disorders and immune factors
      affecting graft versus host disease in stem-cell transplant (SCT) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Immune Reconstitution in Study Participants</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of immune reconstitution in study participants treated for hematologic disorders and malignancies including SCT donors and recipients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Treatment for Malignancy/Failure</arm_group_label>
    <description>Patients undergoing treatment for hematologic malignancy or bone marrow failure state. Blood draws may be collected at certain time points during which the patient is being evaluated for a response to treatment. Collections may be acquired at the following timeframes:
At the time of diagnosis (prior to any treatment or therapy); and
Post each line of therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Standard-of-Care SCT</arm_group_label>
    <description>All cancer patients being treated with standard-of-care SCT will be studied. Blood draws may be collected within 30 days pre-transplant; Post-transplant 14 days (± 2 days), 21 days (± 4 days), 30 days (+/- 7 business days); 60 days (+/- 21 business days); 100 days (+/- 30 business days); 6 months (+/- 30 business days); 1 year (+/- 30 business days) and annually (+/- 60 business days) thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.</description>
    <arm_group_label>Arm A: Treatment for Malignancy/Failure</arm_group_label>
    <arm_group_label>Arm B: Standard-of-Care SCT</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples Marrow Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Arm A: Will include subjects selected from all patients presenting to the clinical services
        of the Division of Hematology/Oncology, for treatment of hematologic disorders. This will
        include patients with a broad range of hematologic malignancies and bone marrow failure
        states.

        Arm B: Will include subjects selected from all patients presenting to the clinical services
        of the Adult Cell Transplant Program as donors or recipients for SCT. All donors will have
        been cleared for clinical marrow or peripheral blood stem cell donation, and will be
        expected to be generally healthy.

        Both arms will include subjects ranging in age from late adolescence to approximately age
        75; individuals of both sexes; and a wide variety of ethnic backgrounds.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Arm A:

          -  Patients presenting to the clinical services of the Division of Hematology/Oncology,
             for treatment of hematologic disorders.

          -  Age ranging from late adolescence to approximately age 75.

          -  Including patients with a broad range of hematologic malignancies and bone marrow
             failure states.

        Arm B:

          -  Stem Cell Transplant Donor

          -  Stem Cell Transplant Recipient

          -  Age range from late adolescence to age 75

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krishna V Komanduri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Komaduri, MD</last_name>
      <phone>305-243-6356</phone>
      <email>kkomanduri@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Krishna Komaduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wieder, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCT</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

